Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Retrophin Inc    RTRX

RETROPHIN INC (RTRX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Retrophin : Ex-lawyer for pharma executive Shkreli convicted of aiding fraud scheme

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/28/2017 | 03:18am CEST
FILE PHOTO:    Former drug company executive Martin Shkreli exits U.S. District Court after being convicted of securities fraud, in the Brooklyn borough of New York City

(Reuters) - A New York lawyer who once advised Martin Shkreli was convicted on Wednesday of helping him defraud a pharmaceutical company, a charge a different jury cleared the drug executive of when it found him guilty of securities fraud earlier this year.

Evan Greebel, who was outside counsel to Shkreli's former company Retrophin Inc, was found guilty by a federal jury in Brooklyn of charges he conspired to commit wire fraud and securities fraud, prosecutors said.

"We are shocked by the verdict," said Reed Brodsky, a lawyer for Greebel. "We will continue to fight for justice for Evan Greebel and his family."

Acting U.S. Attorney Bridget Rohde in Brooklyn said the verdict sent a message to lawyers that they will be held accountable when they "use their legal expertise to facilitate the commission of crime."

The verdict came after a different jury in August found Shkreli guilty of defrauding hedge fund investors, but not guilty of conspiring with Greebel to steal from Retrophin. He has denied wrongdoing.

Greebel, 44, was a partner at the law firm Katten Muchin Rosenman when he was working for Retrophin. He later joined the firm Kaye Scholer, but resigned after his arrest in December 2015.

Shkreli, 34, became notorious in 2015 when he raised the price of anti-parasitic drug Daraprim to $750 a pill, from $13.50, as chief executive of Turing Pharmaceuticals. The price hike is unrelated to the criminal case.

The charges he and Greebel faced related to Shkreli's management of his previous drug company, Retrophin, and of two hedge funds, MSMB Capital and MSMB Healthcare, from 2009 to 2014.

Prosecutors have said that Shkreli lied about the funds' finances to lure investors and concealed devastating trading losses. They said he paid investors back with money and shares stolen from Retrophin, which he founded in 2011.

Prosecutors said Greebel assisted Shkreli in defrauding Retrophin through a series of settlement and sham consulting agreements.

In September, following his conviction, Shkreli was jailed after he offered a $5,000 reward in a posting on Facebook for a strand of former presidential candidate Hillary Clinton's hair. That prompted U.S. District Judge Kiyo Matsumoto to revoke his bail.

Greebel denied wrongdoing, and at trial, his lawyers sought to distance their client from Shkreli, whose provocative public behavior earned him the nickname "pharma bro."

Brodsky told jurors during his opening statement that Shkreli lied to Greebel just as he lied to investors.

Greebel was also accused of conspiring with Shkreli to exercise secret control over Retrophin shares belonging to several other shareholders. Shkreli was found guilty of that charge during his trial.

(Reporting by Jan Wolfe and Nate Raymond; Editing by Frances Kerry and Tom Brown)

By Jan Wolfe and Nate Raymond

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RETROPHIN INC
07/16RETROPHIN : to Report Second Quarter 2018 Financial Results
AQ
07/12RETROPHIN : to Report Second Quarter 2018 Financial Results
AQ
07/06RETROPHIN : 10-k/a - management's discussion and analysis of financial condition..
AQ
06/18RETROPHIN : Announces Expansion of Intellectual Property Estate for Sparsentan w..
AQ
06/14Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan ..
GL
06/05RETROPHIN : Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Op..
AQ
06/04Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN O..
GL
05/24Retrophin to Present at Upcoming Investor Conferences
GL
05/24RETROPHIN : Receives Workplace Excellence Award
AQ
05/23RETROPHIN : Receives Workplace Excellence Award
AQ
More news
News from SeekingAlpha
06/14Retrophin expands intellectual property estate for sparsentan with newly issu.. 
05/30Learning From The Best - How Joseph Edelman (Perceptive Advisors) Invests 
05/01Retrophin's (RTRX) CEO Steve Aselage on Q1 2018 Results - Earnings Call Trans.. 
05/01Retrophin beats by $0.31, misses on revenue 
04/30Notable earnings after Tuesday?s close 
Financials ($)
Sales 2018 175 M
EBIT 2018 -63,5 M
Net income 2018 -60,1 M
Finance 2018 175 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 6,20x
EV / Sales 2019 5,57x
Capitalization 1 262 M
Chart RETROPHIN INC
Duration : Period :
Retrophin Inc Technical Analysis Chart | RTRX | US7612991064 | 4-Traders
Technical analysis trends RETROPHIN INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 38,7 $
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Stephen J. Aselage President, Chief Executive Officer & Director
Gary A. Lyons Chairman
Neil F. McFarlane Chief Operating Officer
Laura M. Clague CFO, Principal Accounting Officer & Senior VP
William E. Rote Senior VP, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
RETROPHIN INC46.84%1 262
GILEAD SCIENCES7.65%100 276
VERTEX PHARMACEUTICALS20.87%46 157
REGENERON PHARMACEUTICALS-2.65%38 776
GENMAB9.33%10 846
NEUROCRINE BIOSCIENCES, INC.33.79%9 279